AMAG PHARMACEUTICALS, INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 1981-01-01

Employees: 440

Market Cap: -

Website: http://www.amagpharma.com

Clinical Trials

Study to Evaluate Rate of Nausea in Healthy Premenopausal Female Subjects Treated With Single Dose of Bremelanotide Alone or With Zofran

Phase 1

Completed

Conditions: Nausea

Interventions: Drug: Bremelanotide
Drug: Placebo
Drug: Zofran

First Posted Date: 2019-06-04

Last Posted Date: 2022-04-04

Lead Sponsor: AMAG Pharmaceuticals, Inc.

Target Recruit Count: 228

Registration Number: NCT03973047

Locations: 🇺🇸
ICON Early Phase Serrvices, LLC, San Antonio, Texas, United States

A Study to Evaluate Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects

Phase 3

Recruiting

Conditions: Iron Deficiency Anemia

Interventions: Drug: ferumoxytol
Drug: Iron sucrose

First Posted Date: 2019-03-28

Last Posted Date: 2024-08-12

Lead Sponsor: AMAG Pharmaceuticals, Inc.

Target Recruit Count: 75

Registration Number: NCT03893045

Locations: 🇺🇸
Biomedical Research LLC, Miami, Florida, United States
🇺🇸
Gwinnett Research Institute, Buford, Georgia, United States
🇵🇱
Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wroclawiu, Wrocław, Poland

and more 12 locations

A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD)

Phase 3

Recruiting

Conditions: Chronic Kidney Disease; Iron Deficiency Anemia

Interventions: Drug: Ferumoxytol
Drug: Iron sucrose

First Posted Date: 2018-08-08

Last Posted Date: 2024-08-12

Lead Sponsor: AMAG Pharmaceuticals, Inc.

Target Recruit Count: 129

Registration Number: NCT03619850

Locations: 🇺🇸
Memorial Healthcare System, Hollywood, Florida, United States
🇺🇸
West Virginia University, Morgantown, West Virginia, United States
🇵🇱
Polish Mother's Memorial Hospital Research Institute, Łódź, Poland

and more 18 locations

Study of the Efficacy and Safety of AMAG-423 (Digoxin Immune Fab) in Antepartum Subjects With Severe Preeclampsia

Phase 2

Terminated

Conditions: Severe Preeclampsia

Interventions: Other: Placebo
Biological: AMAG-423 (digoxin immune fab)

First Posted Date: 2017-01-02

Last Posted Date: 2022-04-04

Lead Sponsor: AMAG Pharmaceuticals, Inc.

Target Recruit Count: 59

Registration Number: NCT03008616

Locations: 🇺🇸
University of South Alabama, Mobile, Alabama, United States
🇺🇸
University Hospitals Case Medical Center-Case Western Reserve University (CWRU), Cleveland, Ohio, United States
🇺🇸
Regional Obstetrical Consultants, Chattanooga, Tennessee, United States

and more 15 locations

Comparing Bioavailability When Preservative-free Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) is Administered as an Intramuscular Manual Injection or as a Subcutaneous Injection Using an Auto-injector in Healthy Post-menopausal Women

Phase 1

Completed

Conditions: Comparing Bioavailability When Makena® is Administered in Healthy Post-menopausal Women

Interventions: Drug: Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)

First Posted Date: 2016-10-21

Last Posted Date: 2022-04-28

Lead Sponsor: AMAG Pharmaceuticals, Inc.

Target Recruit Count: 122

Registration Number: NCT02940522

Study Assessing Injection Pain of Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) When Administered Via Subcutaneous Auto-injector vs Intramuscular Injection Via Needle and Syringe in Healthy Post-menopausal Women

Phase 3

Terminated

Conditions: Assessing Injection Pain of Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) in Healthy Post-menopausal Women

Interventions: Drug: Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)

First Posted Date: 2016-10-19

Last Posted Date: 2022-04-21

Lead Sponsor: AMAG Pharmaceuticals, Inc.

Target Recruit Count: 60

Registration Number: NCT02937766

Locations: 🇺🇸
Lotus Clinical Research, LLC, Pasadena, California, United States

A Phase III Safety Study of Ferumoxytol Compared to Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia (IDA)

Phase 3

Completed

Conditions: Iron Deficiency Anemia

Interventions: Drug: Ferumoxytol
Drug: FCM

First Posted Date: 2016-03-01

Last Posted Date: 2023-07-25

Lead Sponsor: AMAG Pharmaceuticals, Inc.

Target Recruit Count: 2014

Registration Number: NCT02694978

Locations: 🇵🇷
Clinical Trial Site, Ponce, Puerto Rico
🇺🇸
AMAG Pharmaceuticals, Inc., Waltham, Massachusetts, United States

A Trial of Ferumoxytol for the Episodic Treatment of Iron Deficiency Anemia in Pediatric Participants With Chronic Kidney Disease

Phase 3

Terminated

Conditions: Iron Deficiency Anemia

Interventions: Drug: Ferumoxytol

First Posted Date: 2010-12-22

Last Posted Date: 2022-04-28

Lead Sponsor: AMAG Pharmaceuticals, Inc.

Target Recruit Count: 8

Registration Number: NCT01264679

Locations: 🇺🇸
AMAG Pharmaceuticals, Inc., Waltham, Massachusetts, United States

Compare Efficacy/Safety of Repeat Doses of Ferumoxytol With Iron Sucrose in CKD Subjects With IDA and on Hemodialysis

Phase 4

Completed

Conditions: Chronic Kidney Disease(CKD)
Iron Deficiency Anemia Treatment

Interventions: Drug: Ferumoxytol
Drug: Iron Sucrose

First Posted Date: 2010-10-25

Last Posted Date: 2022-04-21

Lead Sponsor: AMAG Pharmaceuticals, Inc.

Target Recruit Count: 296

Registration Number: NCT01227616

Locations: 🇬🇧
For additional information regarding investigative sites for this trial , contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, London, United Kingdom
🇨🇦
For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) , or speak with your personal physician, Montréal, Canada
🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, London, United Kingdom

A Trial of Ferumoxytol for the Treatment of Iron Deficiency Anemia in Pediatric Participants With Nondialysis-Dependent Chronic Kidney Disease

Phase 3

Terminated

Conditions: Iron Deficiency Anemia
Nondialysis-dependent Chronic Kidney Disease

Interventions: Drug: Oral Iron
Drug: Ferumoxytol

First Posted Date: 2010-07-01

Last Posted Date: 2022-04-28

Lead Sponsor: AMAG Pharmaceuticals, Inc.

Target Recruit Count: 14

Registration Number: NCT01155388

Locations: 🇺🇸
AMAG Pharmaceuticals, Inc., Waltham, Massachusetts, United States

Home Terms & Conditions Privacy Policy